Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Ardelyx with a $15 price target but acknowledges the departure of its Chief Commercial Officer Susan Rodriguez is not a positive. Management offered little color on the exit this morning on a call, says the analyst, who views the timing as “more than just a little bit odd.” Piper thinks the move could be related to some kind of strategic disagreement, adding it is “in the dark as much as anyone.” Ardelyx would do well to provide more color on the departure, the firm contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
- Ardelyx presents additional data at 2024 DDW conference on IBSRELA
- Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
- Ardelyx present additional data at NKF 2024 on XPHOZAH
- Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)